Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management

  • Habas E
  • Eledrisi M
  • Khan F
  • et al.
N/ACitations
Citations of this article
143Readers
Mendeley users who have this article in their library.

Abstract

Serum calcium concentration is the main determinant of parathyroid hormone (PTH) release. Defect in the activation of vitamin D in the kidneys due to chronic kidney disease (CKD) leads to hypocalcemia and hyperphosphatemia, resulting in a compensatory increase in parathyroid gland cellularity and parathyroid hormone production and causing secondary hyperparathyroidism (SHP). Correction and maintenance of normal serum calcium and phosphate are essential to preventing SHP, hungry bone disease, cardiovascular events, and anemia development. Understanding the pathophysiology of PTH and possible therapeutic agents can reduce the development and associated complications of SHP in patients with CKD. Medical interventions to control serum calcium, phosphate, and PTH such as vitamin D analogs, calcium receptor blockers, and parathyroidectomy are needed in some CKD patients. In this review, we discuss the pathophysiology, clinical presentation, and management of SHP in CKD patients.

Cite

CITATION STYLE

APA

Habas, E., Eledrisi, M., Khan, F., & Elzouki, A.-N. Y. (2021). Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management. Cureus. https://doi.org/10.7759/cureus.16388

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free